Drug intelligence / Profile preview

Pelvilen Dual Act Microgranuli

Development stage
Unknown
Lead developer
Epitech
Modality
Small Molecules
Administration
Oral, Sublingual
01

Overview

Pelvilen Dual Act Microgranuli is an ALIAmide-based oral and sublingual microgranule formulation developed by Epitech Group for the management of chronic pelvic pain. It contains a combination of ultra-micronized palmitoylethanolamide (PEA) and m-PEAPOL, which is PEA co-micronized with the antioxidant polydatin (trans-polydatin). The product utilizes the ALIA (Autacoid Local Inflammation Antagonism) mechanism, where PEA acts to modulate the activation of mast cells and other non-neuronal immune cells, such as microglia and astrocytes, thereby reducing neuroinflammation and peripheral sensitization in pelvic tissues. Polydatin provides complementary antioxidant activity to mitigate oxidative stress associated with chronic inflammation. It is indicated for chronic pelvic pain associated with conditions such as endometriosis, interstitial cystitis, recurrent cystitis, chronic prostatitis, and irritable bowel syndrome.

Brand names
Pelvilen Dual Act Microgranuli
Other names
Pelvilen Dual ActPELVILEN DUAL ACT MICROGRANULI 20 BUSTINEPELVILEN DUAL ACT MICROGRANULI 60 BUSTINEpalmitoylethanolamide + polydatin
02

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)CNR2 (Cannabinoid receptor type 2)GPR55 (G protein-coupled receptor 55)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on Pelvilen Dual Act Microgranuli.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pelvilen Dual Act Microgranuli.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call